The earnings call highlighted significant positive clinical trial results and a promising regulatory pathway for Inovasarm, which are offset by financial challenges and cash flow concerns. Despite the financial difficulties, the clinical advancements and regulatory progress suggest a positive outlook for the company's drug development efforts.

Company Guidance

During the Veru Inc. investors conference call, the company provided detailed guidance on their clinical-stage drug candidates, particularly focusing on the Phase 2b study outcomes for Inovasarm. The study demonstrated a 100% preservation of lean mass in patients over 60 years old, using Inovasarm in combination with semaglutide, compared to a 66% fat mass loss and 34% lean mass loss in the placebo group. The six-milligram dose of Inovasarm showed a 42% greater fat loss relative to placebo. Furthermore, the safety profile showed no significant adverse events post semaglutide discontinuation. Financially, the company reported a net loss of $7.3 million for the quarter ending June 30, 2025, with research and development costs decreasing to $3 million due to the completion of the Phase 2b study. The call also highlighted the development of a novel modified release formulation of Inovasarm intended for Phase III clinical studies, which has shown promising pharmacokinetic profiles and is protected by global patents through 2037. The company is seeking regulatory clarity from the FDA for its Phase III program, targeting an older population at risk for muscle weakness and falls.

Successful Phase 2b Clinical Trial Results

The Phase 2b clinical trial for Inovasarm showed a 42% greater relative loss of fat mass compared to the placebo group, with a statistically significant preservation of total lean mass. The trial demonstrated a reduction in the proportion of patients experiencing a decline in physical function.

Positive Safety Profile

Inovasarm displayed a positive safety profile in the Phase 2b trial, with no significant adverse events such as gastrointestinal side effects or liver injury. The safety profile was maintained even after discontinuation of semaglutide.

Novel Modified Release Formulation

A new modified release oral formulation of Inovasarm was developed, demonstrating a distinct target product release profile and extended patent protection through 2037.

Optimistic Regulatory Pathway

Veru has scheduled a meeting with the FDA for regulatory clarity on the Phase 3 program, with previous FDA feedback supporting the clinical path forward.

Reduction in Operating Expenses

Research and development costs decreased from $4.8 million to $3 million, and selling, general, and administrative expenses decreased from $5.8 million to $5 million.

Veru (VERU) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VERU Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 11, 2026	2026 (Q1)	- / -	-0.06	―	―	―
Aug 12, 2025	2025 (Q3)	-0.53 / -0.50	-0.7	28.57% (+0.20)	―
May 08, 2025	2025 (Q2)	-0.63 / -0.50	-0.7	28.57% (+0.20)	―
Feb 13, 2025	2025 (Q1)	-0.76 / -0.60	-0.8	25.00% (+0.20)	―
Aug 08, 2024	2024 (Q3)	-0.58 / -0.70	0.7	-200.00% (-1.40)	―
May 08, 2024	2024 (Q2)	-0.53 / -0.70	-4.8	85.42% (+4.10)
Feb 08, 2024	2024 (Q1)	-1.20 / -0.80	-4.6	82.61% (+3.80)	―
Dec 14, 2023	2023 (Q4)	-0.23 / -0.23	-0.51	54.90% (+0.28)	―	―
Aug 10, 2023	2023 (Q3)	-2.03 / 0.70	-2.8	125.00% (+3.50)	―
May 11, 2023	2023 (Q2)	-3.33 / -4.80	-1.8	-166.67% (-3.00)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VERU Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$3.59	$3.17	-11.70%
May 08, 2025	$5.01	$5.22	+4.19%
Feb 13, 2025	$5.50	$5.26	-4.36%
Aug 08, 2024	$7.69	$8.10	+5.33%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Veru (VERU) report earnings?

Veru (VERU) is schdueled to report earning on Feb 11, 2026, Before Open (Confirmed).

What is Veru (VERU) earnings time?

Veru (VERU) earnings time is at Feb 11, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VERU EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing